IndraLab
Statements
"Treatment of cells with GPCR agonists such as endothelin- 1 (ET-1), thrombin, bombesin, and lysophosphatidic acid (LPA) transactivates ErbB1 (reviewed by Zwick et al. [48]). Mechanistically, the process involves rapid stimulation of metalloproteinases followed by cleavage of an ErbB1 ligand precursor, e.g., pro-HB-EGF [49], whose binding activates ErbB1 and downstream signaling pathways"